Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

European Journal of Cancer

Volumn 42, Issue 8, 2006, Pages 1083-1092

  Spry, N A ^a,b,c   Kristjanson, L ^c   Hooton, B ^b   Hayden, L ^g   Neerhut, G ^d   Gurney, H ^e   Corica, T ^b   Korbel, E ⁱ   Weinstein, S ^f   McCaul, K ^h  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

^d GEELONG HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f Hollywood Priv Hosp Monash Avenue   (Australia)

^g LIVERPOOL HOSPITAL   (Australia)

^h CURTIN UNIVERSITY   (Australia)

ⁱ SUTHERLAND HOSPITAL   (Australia)

Author keywords

Androgen suppression; Drug therapy; Flutamide; Health related quality of life; Leuprolide; Prostate cancer; Testosterone recovery

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; APPETITE DISORDER; ARTICLE; BLOATING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONVALESCENCE; DETERIORATION; DIARRHEA; DYSPNEA; DYSURIA; EDEMA; ENTEROPATHY; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MASCULINITY; MULTICENTER STUDY; NAUSEA; PAIN; PRIORITY JOURNAL; PROCTITIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; QUALITY OF LIFE; RATING SCALE; SEX DIFFERENTIATION DISORDER; SIDE EFFECT; SLEEP DISORDER; SYMPTOMATOLOGY; TREATMENT FAILURE; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; COMPARATIVE STUDY; LONGITUDINAL STUDY; MIDDLE AGED; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; TUMOR RECURRENCE;

AGED; ANDROGEN ANTAGONISTS; FLUTAMIDE; HUMANS; LEUPROLIDE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; TESTOSTERONE;

EID: 33746387985     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.029     Document Type: Article

References (22)

1. McCredie M., and Cox B. Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust 169 1 (1998) 9-10
2. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 163 6 (2000) 1632-1642
3. Rashid M.H., and Chaudhary U.B. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 9 3 (2004) 295-301
4. Australian Institute of Health and Welfare. Cancer in Australia 1999. Internet. 22-11-2002 [Electronic Citation].
5. Ransohoff D.F., McNaughton C.M., and Fowler F.J. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 113 8 (2002) 663-667
6. Chodak G.W. Comparing treatments for localized prostate cancer - persisting uncertainty. JAMA 280 11 (1998) 1008-1010
7. Pether M., Goldenberg S.L., Bhagirath K., and Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 10 2 (2003) 1809-1814
8. Aaronson NK, van Andel G. An international field of the reliability and validity of the QLQ-C30 and a disease-specific questionnaire module (QLQ-PR25) for assessing quality of life of patients with prostate cancer. European Organization for Research and Treatment of Cancer study protocol (15011). Brussels; 2002.
9. da-Silva F.C., Fossa S.D., Aaronson N.K., Serbouti S., Denis L., Casselman J., et al. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial30853. Eur J Cancer 32A 1 (1996) 72-77
10. Osoba D., Rodrigues G., Myles J., Zee B., and Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 1 (1998) 139-144
11. STATA v.8; 2005.
12. Fayers P, Weeden S, Currana D. EORTC QLQC-30 reference values. Brussels: EORTC Qualify of Life Study Group; 1998.
13. Fayers P. Department of Public Health - University of Aberdeen; 2005 [Personal Communication].
14. Schroder F.H. Screening, early detection, and treatment of prostate cancer: a European view. Urology 46 3 Suppl. A (1995) 62-70
15. Litwin M.S., Shpall A.I., Dorey F., and Nguyen T.H. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 21 4 (1998) 327-332
16. Moinpour C.M., Savage M.J., Troxel A., Lovato L.C., Eisenberger M., et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 90 20 (1998) 1537-1544
17. Albertsen P.C., Aaronson N.K., Muller M.J., Keller S.D., and Ware-JE J. Health-related quality of life among patients with metastatic prostate cancer. Urology 49 2 (1997) 207-216
18. van Andel G., Kurth K.H., and de Haes J.C. Quality of life in patients with prostatic carcinoma: a review and results of a study in N+ disease. Prostate-specific antigen as predictor of quality of life. Urol Res 25 Suppl. 2 (1997) S79-S88
19. Potosky A.L., Knopf K., Clegg L.X., Albertsen P.C., Stanford J.L., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19 17 (2001) 3750-3757
20. Herr H.W., and O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163 6 (2000) 1743-1746
21. Sato N., Akakura K., Isaka S., Nakatsu H., Tanaka M., et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64 2 (2004) 341-345
22. Allan C.A., and McLachlan R.I. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol (Oxf) 60 6 (2004) 653-670